Company Profile
Alector Stock Price, News & Analysis
- Ticker:
- ALEC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.83 USD (+22.82%)
Close
Last updated: August 6, 2026
216M USD
Market cap
Why the stock is moving
The latest monitored company update is “Alector Reports Second Quarter 2026 Financial Results and Provides Business Update.” The corresponding closing-price reaction is not yet available.
Company overview
Neurodegeneration and Immunology
Alector develops therapies for neurodegenerative diseases using insights from human genetics, immunology and neuroscience. Its programs seek to remove toxic proteins, replace deficient proteins and restore immune function in the brain.
Alector Brain Carrier
The Alector Brain Carrier platform is designed to transport therapeutic payloads across the blood-brain barrier. It is being applied to antibodies, enzyme-replacement therapies and siRNA molecules.
AL037 and AL137
AL037 and AL137 are brain-carrier-enabled antibodies targeting a toxic pyroglutamate amyloid-beta epitope in Alzheimer's disease. The candidates share the same antibody but use carrier domains with different binding properties.
AL050
AL050 is an ABC-enabled GCase enzyme-replacement therapy intended to restore lysosomal function in Parkinson's disease while improving delivery into the brain.
Tau siRNA Programs
AL064 and its optimized successor AL164 use the brain carrier to deliver tau-directed siRNA for Alzheimer's disease and other tauopathies. Additional siRNA research targets alpha-synuclein and NLRP3.
Future catalysts
IND submission for AL037/AL137 in the first quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Alector (ALEC)?
Alector (ALEC) most recently closed at 1.83 USD, a +22.82% move versus the previous session.
What is the market cap of Alector (ALEC)?
Alector currently has a market capitalization of 216M USD on BioPharmSignal.
What does Alector do?
Neurodegeneration and Immunology Alector develops therapies for neurodegenerative diseases using insights from human genetics, immunology and neuroscience. Its programs seek to remove toxic proteins, replace deficient proteins and restore immune function in the brain. Alector Brain Carrier The Alector Brain Carrier platform is designed to transport...
On which exchange is ALEC stock listed?
Alector (ALEC) is associated with NASDAQ, United States, Biopharma.
What is Neurodegeneration?
Neurodegeneration and Immunology Alector develops therapies for neurodegenerative diseases using insights from human genetics, immunology and neuroscience.
Which conditions is Alector targeting with Neurodegeneration?
Alector is associated with immunology, neuroscience, genetic disease based on its company overview and current catalyst commentary.
How does Alector describe recent progress with Neurodegeneration?
IND submission for AL037/AL137 in the first quarter of 2027.
What is Immunology?
Neurodegeneration and Immunology Alector develops therapies for neurodegenerative diseases using insights from human genetics, immunology and neuroscience.